DeCure for Signet Ring Cell Gastric Adenocarcinoma
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Signet Ring Cell Gastric Adenocarcinoma — screening already-approved drugs against its 49-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSignet Ring Cell Gastric Adenocarcinoma maps to a 49-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for signet ring cell gastric adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ras homolog family member A (RHOA) — RHOA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5C4M · 1.3 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
Between 1965 and 1985, 51 of 1500 gastric cancer patients (3.4%) who underwent gastric resection had signet ring cell carcinoma. These patients tended to be younger and female; their tumours were smaller, involved the stomach body, showed less serosal invasion, and were less likely to have lymph node metastases. Early mucosal and submucosal cancer was present in 54.9% of signet ring cell patients versus 24.6% of patients with other gastric cancer types. A non-curative resection was performed in 15.7% of signet ring cell cases. The 5-year survival rate was 74.5% for signet ring cell patients and 52.4% for other gastric cancer patients (P < 0.01). The authors concluded that the lesion is less extensive in signet ring cell gastric cancer, and these patients probably can expect longer survival.
A 2020 retrospective, propensity score-matched study evaluated neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric signet ring cell carcinoma. After propensity score matching, the study found that neoadjuvant chemotherapy provided no survival benefit. Multivariate analyses conducted before and after matching showed that neoadjuvant chemotherapy was not a prognostic factor. The authors concluded that for resectable gastric signet ring cell carcinoma, upfront surgery should be the primary therapy.
A 2018 study described gastric signet ring cell carcinoma as a highly malignant phenotype with no known effective molecularly targeted therapies. The authors stated that limited knowledge of the molecular mechanisms underlying signet ring cell carcinoma hinders the development of therapeutic strategies. They performed targeted-sequencing and comprehensive molecular profiling, but the abstract does not report any specific mutations, response rates, or survival data from that profiling.
What is still missing is a molecularly defined target that can be drugged, a clinical trial design that shows benefit for any systemic therapy beyond surgery, and patient stratification that separates early-stage cases (which have a relatively good prognosis with surgery alone) from advanced cases where no effective medical therapy has yet been demonstrated.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer · 1992 · 140 citations · open access
Signet ring cell carcinoma of the stomach
AbstractBetween 1965 and 1985, 51 of 1500 patients (3.4%) with gastric cancer who had gastric resection had signet ring cell gastric cancer. Patients with this form of cancer tended to be younger and female; the tumors were smaller and involved the stomach body, serosal invasion was less prominent, and lymph node metastases were less likely to be present. Early mucosal and submucosal cancer was present in 54.9% of the patients with the signet ring cell and in 24.6% with other types of gastric cancer. In 15.7% of patients with signet ring cell cancer, a noncurative resection was performed. The 5-year survival rate was 74.5% for patients with signet ring cell cancer and 52.4% for those with other types of gastric cancer (P less than 0.01). In patients with signet ring cell gastric cancer, the lesion is less extensive; thus, these patients probably can expect a longer survival time.
World Journal of Gastroenterology · 2020 · 36 citations · open access
Neoadjuvant chemotherapy <i>vs</i> upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study
AbstractBACKGROUND: The benefit of neoadjuvant chemotherapy for patients with signet-ring cell carcinoma of the stomach is controversial. AIM: To evaluate the perioperative and long-term outcomes of neoadjuvant chemotherapy for locally advanced gastric signet-ring cell carcinoma. METHODS: surgery-first treatment in the selected patients. RESULTS: = 0.192), respectively, after PSM. Multivariate analyses conducted before and after PSM showed that NAC was not a prognostic factor. CONCLUSION: Neoadjuvant chemotherapy provides no survival benefit in patients with locally advanced gastric signet-ring cell carcinoma. For resectable gastric signet-ring cell carcinoma, upfront surgery should be the primary therapy.
Case Reports in Medicine · 2015 · 2 citations · open access
Intramucosal Signet Ring Cell Gastric Cancer Diagnosed 15 Months after the Initial Endoscopic Examination
AbstractThe size and shape of intramucosal signet ring gastric cancer in this case remained endoscopically unchanged for 15 months. Laparoscopy-assisted distal gastrectomy was performed, and immunohistochemical analysis revealed Ki-67 and p53 mutations to be negative in this case. Signet ring gastric cancer has long been thought to confer a worse prognosis than other forms of gastric cancer; however, our case did not progress to advanced gastric cancer for 15 months.
Annals of Oncology · 2018 · 1 citations · open access
Targeted-sequencing and comprehensive molecular profiling of gastric signet ring cell carcinoma
AbstractIntroduction: Gastric cancer is a heterogeneous disease with various molecular subtypes. Signet ring cell carcinoma is characterized by a highly malignant phenotype of gastric cancer with no known effective molecularly targeted therapies. The limited knowledge of the molecular mechanisms underlying signet ring cell carcinoma hinders the development of therapeutic strategies.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
